TLPH: Nafamostat's pivotal CRRT study nears completion, with strong market and guideline support
Pivotal study for nafamostat in CRRT anticoagulation is nearing completion, with top-line data expected by year-end and a PMA filing planned soon after. Updated market analysis shows a larger, growing opportunity, and recent KDIGO guidelines now recommend nafamostat, supporting its anticipated firs…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.